Biocon has announced the commercial launch of Yesafili (aflibercept-jbvf) in the United States market, with commercial sales commencing on August 3, 2026. According to reports from CNBC TV18, YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions. The product serves as a biosimilar of its reference product EYLEA (aflibercept) 2 mg, positioning it as a cost-effective alternative in the ophthalmology treatment market. The company notified the Bombay Stock Exchange and National Stock Exchange of India Limited regarding the launch pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as signed by Rajesh U. Shanoi, Company Secretary and Compliance Officer. Shreehas Tambe, CEO & Managing Director, Biocon Ltd., emphasized that "The launch of Yesafili in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions."
The launch targets a significant market opportunity, as an estimated 19.8 million Americans are living with age-related macular degeneration. According to CNBC TV18, US sales of aflibercept reached around $5.89 billion in 2023, highlighting the substantial market potential for Yesafili. Age-related macular degeneration is a leading cause of irreversible vision loss in adults with over 60, making it a significant health concern as the population ages. Yesafili is indicated for the treatment of several serious eye conditions, including neovascular (wet) AMD, macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with AMD, with 1.49 million (0.94%) living with vision threatening conditions, as reported by Biocon.
The product received previously approved status and granted interchangeable designation by the U.S. Food and Drug Administration in May 2024. As reported by CNBC TV18, this interchangeable designation allows substitution at the pharmacy level in accordance with state laws, providing greater accessibility for patients requiring ophthalmology treatments. The vial carries interchangeable status while the pre-filled syringe has provisional interchangeability, which affects which presentations can be substituted freely. This regulatory approval positions Yesafili as one of the first interchangeable biosimilars to Eylea 2 mg in the market. The approval for Yesafili relied on data from the Phase 3 INSIGHT Study, which compared the biosimilar against Eylea 2 mg in patients with Diabetic Macular Edema. The study demonstrated no clinically meaningful differences between the two products regarding pharmacokinetics, safety, efficacy, and immunogenicity. The approval was based on a comprehensive package of analytical, nonclinical and clinical data that confirmed YESAFILI is highly similar to Eylea 2 mg.
For a company of Biocon's profile, the launch fits a well-established strategy of building scale in the US biosimilars market, where it has already commercialized a portfolio across diabetes, oncology and immunology. As reported by Business Upturn, ophthalmology biosimilars are a high value opportunity because the reference products command large sales and the patient populations are growing with an ageing demographic. The interchangeable status is a critical differentiator, as it permits automatic substitution at pharmacies without additional physician intervention, potentially accelerating adoption rates compared to non-interchangeable biosimilars. The competitive dynamic is that Eylea faces multiple biosimilar entrants, so Yesafili's interchangeable status is a key advantage in a crowded field. The India angle is intrinsic, since Biocon is one of India's leading biopharmaceutical companies and a global pioneer in biosimilars, and the launch reinforces the position of Indian pharma in supplying complex, high value biologic medicines to regulated Western markets. Tambe noted that this milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, advancing access to life-changing medicines for patients around the world.
Biocon has been active across multiple markets with recent regulatory approvals. As reported by CNBC TV18, last week, Biocon's Canadian subsidiary received approval from Health Canada for the Yesintek (ustekinumab) Autoinjector, offering patients a treatment option in Canada that is not available with the originator product. Additionally, Biocon's Malaysia unit received European Medicines Agency approval for a new drug product fill finish line for Semglee (insulin glargine), with supplies to Europe estimated to begin from the second quarter of the ongoing fiscal. Historical stock returns show positive momentum with +9.01% gains over one year and +9.40% returns over five years. The commercialization of Yesafili positions Biocon to capture share in a mature but growing therapeutic area, with the economic potential for biosimilar penetration being substantial given the nearly 20 million Americans affected by AMD.
